Navigation Links
InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin

SACRAMENTO, Calif., Oct. 23 /PRNewswire/ -- InVitria has released data that shows that Lacromin, a recombinant growth factor for cell culture media outperforms transferrin and provides a cost-effective solution to rising transferrin costs. Because Lacromin is produced in a completely animal-free system, it provides improved productivity and safety over animal-derived alternatives including bovine and human transferrin. In addition data has shown that Lacromin significantly increased the productivity of antibody production when compared with these other sources of transferrin.

"We are excited about Lacromin and its success as safer, more productive replacement for transferrin," said Victor Hicks, Vice President and Commercial Director, InVitria. "Lacromin(TM) provides a cost-effective solution to the challenge of rising transferrin costs and increasing concern over the use of animal-derived ingredients in cell culture. Given the FDA's preference for non-animal derived cell culture media ingredients, animal-free recombinant proteins like Lacromin(TM) are a real breakthrough for this market."

InVitria markets Lacromin(TM) to customers that seek a serum-free and animal component free cell culture media source for their biopharmaceutical production.

About Lacromin(TM)

Lacromin(TM) is recombinant human lactoferrin derived from plants. Lacromin(TM) holds many advantages over current cell culture media ingredients:

-- Strong growth factor

Lacromin(TM) has been shown to promote cell growth in many cell lines,

including Chinese Hamster Ovary (CHO) cells and Mouse Hybridoma cells.

-- Outperforms Transferrin

Lacromin(TM) promotes higher cell density and reduces cell doubling

time when compared with Transferrin.

-- Replaces Animal Derived Transferrin

Since Lacromin(TM) is derived from plants, it is free of any viral or

prion contaminant risks.

-- Improves IgG Productivity

In Hybridoma cells, Lacromin(TM) increased IgG productivity by 50%

versus Transferrin and by 6% versus Fetal Bovine Serum (FBS).

About InVitria

InVitria is a global supplier of animal-free products for use in bioprocessing, excipients, research and diagnostics.

InVitria's mission is to develop and supply our customers with products that deliver faster time to market, enhanced productivity, and improved safety.

For more information about InVitria, see our website at

Or Contact:


Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Transgenic Animals
3. Bifidobacterium animalis
4. Bifidobacterium animalis
5. The QIAGEN Guide to Animal Cell Culture
6. The QIAGEN Guide to Animal Cell Culture
7. The QIAGEN Guide to Animal Cell Culture
8. The QIAGEN Guide to Animal Cell Culture
9. The QIAGEN Guide to Animal Cell Culture
10. The QIAGEN Guide to Animal Cell Culture
11. An Animal-Free DNase I
Post Your Comments:
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: ) ... financial services, but it also plays a fundamental part in ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):